John Fletcher

Mr. Fletcher has more than 30 years of strategy and financing experience across the pharmaceutical and healthcare industry. In 1983, Mr. Fletcher founded Fletcher Spaght, Inc., a consulting firm that provides growth-focused strategy assistance to client companies, and since its founding has served as its Chief Executive Officer. Since 2001, Mr. Fletcher has also served as the Managing Partner of Fletcher Spaght Ventures, a venture capital fund. Mr. Fletcher’s current and past board experience includes both public and private companies. Mr. Fletcher currently serves on the boards of Repro Med Systems, Inc. (aka Koru Medical), ClearPoint Neuro, Inc., and Axcelis Technologies, Inc., all of which are public companies. He is Board Chairman at Koru, ClearPoint and Metabolon(privately held). Mr. Fletcher previously served on the boards of The Spectranetics Corporation, Marina Biotechnology, Autoimmune, Inc., Fischer Imaging Corp., Panacos Pharmaceuticals Inc., and NMT Medical Inc., all of which are public companies, and on the private boards of GlycoFi, Inc., Quick Study Radiology Inc., Pilot Software and Xvionics. In addition, Mr. Fletcher has served on the boards of many academic and non-profit institutions. Mr. Fletcher worked on the $2 billion acquisition of Spectranetics by Koninklijke Philips N.V. (Royal Philips) and the $400 million acquisition of GlycoFi by Merck & Co., Inc., and received the National Association of Corporate Directors (NACD) Director of the Year Award in 2018, reflecting the significant turnarounds at Spectranetics and Axcelis. Mr. Fletcher is a graduate of Southern Illinois University (MBA), Central Michigan University (Master’s Degree in International Finance), and George Washington University (BA) and has served as an instructor in International Business at the Wharton School of Business, and as a Captain and jet pilot in the United States Air Force.